Hikma Highlights Long-Term Importance Of Biosimilars
CEO Siggi Olafsson Discusses The Evolution Of Hikma’s Injectables Business
Executive Summary
Playing in biosimilars is essential for firms that want to lead in the sterile injectables space, Hikma CEO Siggi Olafsson commented as he discussed how the firm’s injectables business was expected to evolve over the coming years.